Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.50% | -7.91% | -12.61% | -12.33% | -5.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.50% | -7.91% | -12.61% | -12.33% | -5.82% |
| Cost of Revenue | -39.56% | -33.05% | -30.44% | -24.82% | 65.78% |
| Gross Profit | 55.56% | 25.36% | 8.82% | 1.27% | -43.82% |
| SG&A Expenses | -9.46% | -11.18% | -19.69% | -23.69% | -19.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.50% | -19.34% | -21.81% | -20.28% | 11.48% |
| Operating Income | 91.75% | 65.71% | 62.32% | 57.31% | -247.18% |
| Income Before Tax | 91.77% | 68.58% | 69.68% | 64.88% | -342.98% |
| Income Tax Expenses | -96.29% | -86.91% | -89.16% | -48.49% | 2.79% |
| Earnings from Continuing Operations | 92.39% | 71.53% | 72.96% | 61.22% | -205.06% |
| Earnings from Discontinued Operations | 96.62% | 100.08% | 95.38% | 69.09% | 67.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.76% | 80.50% | 80.70% | 66.12% | 18.27% |
| EBIT | 91.75% | 65.71% | 62.32% | 57.31% | -247.18% |
| EBITDA | 110.63% | 77.88% | 74.66% | -220.53% | -210.62% |
| EPS Basic | 93.57% | 79.57% | 80.25% | 65.68% | 18.16% |
| Normalized Basic EPS | 98.66% | 68.66% | 64.53% | 64.87% | -236.81% |
| EPS Diluted | 93.28% | 79.31% | 79.88% | 65.54% | 17.89% |
| Normalized Diluted EPS | 98.18% | 68.75% | 64.62% | 65.03% | -236.45% |
| Average Basic Shares Outstanding | -4.23% | -3.24% | -2.60% | -2.20% | -1.39% |
| Average Diluted Shares Outstanding | -3.21% | -2.41% | -1.77% | -2.16% | -1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |